Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863222 | 0.88 | TSHR (0.39) | TSHRHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL5184866 | 0.87 | MEN1 (0.38) | TSHRHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL4856975 | 0.84 | TSHR (0.43) | TSHRHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL4858698 | 0.84 | TSHR (0.34) | TSHRHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL4862809 | 0.81 | MEN1 (0.38) | TSHRHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL5184861 | 0.80 | TSHR (0.40) | TSHRHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL4863217 | 0.80 | TSHR (0.40) | TSHRHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL4861217 | 0.78 | MEN1 (0.38) | TSHRHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL4862814 | 0.78 | MEN1 (0.40) | TSHRHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL4858936 | 0.78 | TSHR (0.35) | TSHRHPGDALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456311-B2 | Adamantane derivative, process for producing the same, and photosensitive material for photoresist | IDEMITSU KOSAN CO., LTD. (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080009647-A1 | Adamantane Derivative, Process for Producing the Same, and Photosensitive Material for Photoresist | IDEMITSU KOSAN CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1803708-A1 | ADAMANTANE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND PHOTOSENSITIVE MATERIAL FOR PHOTORESIST | IDEMITSU KOSAN CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009647-A1 | Adamantane Derivative, Process for Producing the Same, and Photosensitive Material for Photoresist | LSS, C1S, DHPS | TSHR 3738/4885HPGD 611/4885ALDH1A1 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.